Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma — Stella

Home/High Grade Astrocytic Tumor/Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

View on ClinicalTrials.gov

Recruiting

Back to High Grade Astrocytic Tumor trials

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Mayo Clinic, Rochester, Minnesota

Key details

Phase

Safety & dosing

Sponsor

Mayo Clinic

Collaborators

NeoImmuneTech, Merck Sharp & Dohme LLC

Enrollment target

~54 participants

Started

January 2023

Primary completion

October 2027

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.